Why the study?
Does the addition of trastuzumab to paclitaxel following doxorubicin and cyclophosphamide increase the risk of cardiac events in patients with HER2-positive operable breast cancer?
Does the addition of trastuzumab to paclitaxel following doxorubicin and cyclophosphamide increase the risk of cardiac events in patients with HER2-positive operable breast cancer?
The addition of trastuzumab following doxorubicin and cyclophosphamide increases the 3-year cumulative incidence of cardiac events by less than 4%, with older age, lower baseline LVEF, and antihypertensive use identified as risk factors.
No takes yet. Share an insight, caveat, or question.
Trastuzumab after AC raises cardiac events modestly; supports monitoring in older/low-LVEF patients while confirming acceptable overall safety in HER2+ breast cancer.
Perez et al. (2008) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: